account_id none on file
legal_name Karyopharm Therapeutics Inc.
ticker KPTI
cik 1503802
domain karyopharm.com
linkedin_company_url https://www.linkedin.com/company/karyopharm-therapeutics-inc/
entry_point_account_id none on file
exchange Nasdaq
sector Health Care
hq Newton, MA, United States
sector index/company/sector/health-care/
calls 1 filings 14 executives 3 family 0
why_nownone on file
calls
We believe our continued focus on disciplined capital allocation and expense management provides us with cash runway to achieve these milestones.
Aug 6, 2024 / receipt, needs a key / Richard, other | earnings call 2024-08-06 | transcript fea46936-5bc4-437e-8b31-8a83f41bde72 | chars 22246-22391 | segment 22
filings
Reaffirming U.S. XPOVIO net product revenue guidance of $115-$130 million in 2026
ir_statement / Sep 15, 2026 / receipt
Established Commercial and Medical Affairs Leadership to Support Potential Launches
ir_statement / Sep 15, 2026 / receipt
Established Commercial and Medical Affairs Leadership to Support Potential Myelofibrosis Launch
ir_statement / Sep 15, 2026 / receipt
Reaffirming U.S. XPOVIO net product revenue guidance of $115-$130 million in 2026
ir_statement / Sep 15, 2026 / receipt
R&D and SG&A Expenses of $230-$245 million
ir_statement / Sep 15, 2026 / receipt
Selling, General & Administrative Expenses 25.9 28.5
ir_statement / Sep 15, 2026 / receipt
Total Operating Expenses $56.0 $62.3
ir_statement / Sep 15, 2026 / receipt
Total Other Expense, net $(44.5) $(12.8)
ir_statement / Sep 15, 2026 / receipt
Hematology Oncology Specialist Orlando, Fl | {"ats": "icims", "city": null, "state": null, "job_id": "2417", "remote": false, "category": "other", "function": "other", "location": null, "job_title": "
company_statement / Sep 8, 2026 / receipt
Hematology Oncology Specialist Pittsburgh | {"ats": "icims", "city": null, "state": null, "job_id": "2419", "remote": false, "category": "other", "function": "other", "location": null, "job_title": "H
company_statement / Aug 27, 2026 / receipt
As Richard discussed, we are actively evaluating a range of financing opportunities and strategic alternatives with the objective of extending our cash runway, preserving strategic flexibility, and ma
company_statement / Aug 13, 2026 / receipt, needs a key
We continue to expect combined R&D and SG&A expenses of $230 million to $245 million in 2026, excluding certain one-time costs that we may incur associated with our endometrial cancer program in evalu
company_statement / Aug 13, 2026 / receipt, needs a key
executives
| Chen Schor | director | - | receipt |
| Mikael Dolsten | director | - | receipt |
| Richard Paulson | President and Chief Executive Officer | - | receipt |
familynone on file
upcoming
| 2026-11-02 | earnings call | scheduled | ir |
changes
| 2021-05-03 | President and Chief Executive Officer, appointed | sec_8k |
| 2020-12-01 | director, appointed | sec_8k |
| 2020-02-28 | director, appointed | sec_8k |
| 2019-07-03 | Executive Vice President, departed | sec_8k |
| 2019-01-18 | Executive Vice President, departed | sec_8k |
| 2017-09-12 | Executive Vice President, appointed | sec_8k |
| 2017-04-03 | Executive Vice President, departed | sec_8k |
| 2015-04-01 | director, appointed | sec_8k |
mcp_package_hint
slug karyopharm-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$